Catalyst Pharmaceutical Partners, Inc. Reports Positive Results From Phase I(a) Clinical Study of CPP-115

CORAL GABLES, Fla., May 22, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced positive results from a Phase I(a) study to evaluate the safety, tolerability and pharmacokinetic (PK) profile of CPP-115, a novel small molecule drug candidate for the potential treatment of epilepsy (initially infantile spasms), cocaine addiction and other select CNS indications. The study results demonstrated that CPP-115 was well tolerated at all six doses administered. This Phase I(a) study is also the first step of an infantile spasms clinical development plan that was discussed with the U.S. Food and Drug Administration's (FDA) Division of Neurology Products during a pre-IND meeting in October 2011.